Useful outcomes from Argos AGS-004 Form 2a trial in patients with HIV

Argos Therapeutics announced today that its Arcelis immunotherapy since the treatment of HIV, AGS-004, demonstrated favourable outcomes with the essential endpoint of viral albatross hold back and a favorable safety and immunogenicity analysis in a decisive review of a Aspect 2a clinical trial. Data payment AGS-004 were presented in a flier at the 18th Colloquy on Retroviruses and Selfish Infections (CROI) in Boston.

In the mug up, AGS-004 was safe and well tolerated with no additional risks observed during structured treatment respite (STI). Argos' monogrammed immunotherapy resulted in an unexpectedly extended delay in viral rebound, shilly-shally to summit viral load during STI and a markedly reduced viral worry when compared to pre-antiretroviral therapy (CRAFT) levels. A calculate of patients were able buy revatio 20 mg to continue the STI old times 12 weeks, and they were capable to initiate CD8+ T chamber proliferative responses to the particular antigens presented in AGS-004.

The unchangeable analysis of the End 2a details reiterates our findings from the previously reported interim analysis that AGS-004 is poetically tolerated, immunogenic, potentially serviceable and unpolluted, said Jean-Pierre Routy, M.D., diva investigator of the about at the McGill University Fitness Concentrate in Montreal. Urge onwards testing last wishes as march that AGS-004 is a doable treatment option in behalf of HIV-1 infected patients.

The Viewpoint 2a trial, AGS-004-001, was a single-arm, open-label think over of the safety, antiviral pursuit, and immunogenicity of AGS-004 in 22 HIV-infected patients in the U.S. Subjects received four doses of AGS-004 while on CRAFTINESS and then interrupted antiretroviral drug treatment while receiving think over drug.

AGS-004 is currently in a Phase 2b clinical side that see fit supplemental show the immunotherapy's efficacy an d sanctuary in the treatment of HIV patients, said Jeff Abbey, president and chief manager manager of Argos. The Phase 2b bone up on is expected to enroll a full of 42 patients in nine sites in the U.S. and Canada, and it is funded not later than the National Institutes of Haleness as function of a $32 million obligation that Argos was awarded in 2006. We are also planning to introduce a State 3 clinical attempt with our Arcelis immunotherapy in renal cell carcinoma, AGS-003, in mid-2011.

The State 2a turn over's cardinal endpoint was to assess the skill of AGS-004 to look up untouched control of HIV-1 replication, as modulated by the proportion of subjects with HIV-1 RNA levels of 1000 copies/mL on at least three anon a punctually points after STI. Secondary endpoints included the immunologic vigour as cautious by CD8+ T chamber responses to AGS-004 psychoanalysis and HIV-1 RNA fix object established after STI versus pre-ART plasma HIV-1 RNA gel point.